Last reviewed · How we verify
Rejuvesol
Rejuvesol is a Small molecule drug developed by Duke University. It is currently FDA-approved.
Rejuvesol is a treatment that has been studied in clinical trials for various conditions, including heart defects, organ failure, inflammation, and sepsis. However, the clinical trial involving Rejuvesol, titled "Rejuvenated, Washed Packed Red Blood Cells in Pediatric Cardiac Surgery," was withdrawn in 2020.
At a glance
| Generic name | Rejuvesol |
|---|---|
| Sponsor | Duke University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Red Cell Rejuvenation for the Attenuation of Transfusion Associated Organ Injury in Cardiac Surgery (PHASE2)
- Rejuvenated RBC and VO2 Max in Healthy Subjects (PHASE4)
- Rejuvenated, Washed Packed Red Blood Cells in Pediatric Cardiac Surgery (PHASE4)
- Rejuvesol® Washed RBC in Sickle Cell Patients Requiring Frequent Transfusions (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rejuvesol CI brief — competitive landscape report
- Rejuvesol updates RSS · CI watch RSS
- Duke University portfolio CI
Frequently asked questions about Rejuvesol
What is Rejuvesol?
Who makes Rejuvesol?
What development phase is Rejuvesol in?
Related
- Manufacturer: Duke University — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing